CDT Equity (CDT) closed at $0.07 on October 30, 2026, down 11.7% from the previous close, on volume of 2,659,596 shares (30-day average 11,374,891).
Data as of October 30, 2026.
CDT Equity Welcomes U.S. Regulatory Development Supporting Expanded Access to Compounded Peptides
Globe Newswire (Fri, 30-Oct 8:32 AM ET)
CDT Partners with Manoira to Explore Enhancing Animal Health Products Ahead of Launch
Globe Newswire (Tue, 27-Oct 8:00 AM ET)
CDT Highlights Sarborg's Solid-Form Patent Filing on a First-in-Class Respiratory Asset
Globe Newswire (Wed, 14-Oct 8:10 AM ET)
CDT Highlights Sarborg's Expanding Quantum Computing IP Portfolio and Application to Drug Discovery
Globe Newswire (Tue, 29-Sep 7:00 AM ET)
CDT Equity Inc. Announces Reverse Stock Split
Globe Newswire (Fri, 25-Sep 8:10 AM ET)
Globe Newswire (Fri, 18-Sep 6:30 AM ET)
Globe Newswire (Thu, 10-Sep 7:00 AM ET)
CDT Provides Capital Update and Confirms No Nasdaq Deficiencies
Globe Newswire (Wed, 2-Sep 5:00 AM ET)
CDT Appoints Co-Founder James Bligh as Chief Executive Officer to Lead Next Phase of Growth
Globe Newswire (Tue, 1-Sep 8:00 AM ET)
CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio
Globe Newswire (Fri, 28-Aug 5:00 AM ET)
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.
CDT Equity trades on the NASDAQ stock market under the symbol CDT.
As of November 2, 2026, CDT stock price was flat at $0.07 with 7,892,045 million shares trading.
CDT has a beta of 4.15, meaning it tends to be more sensitive to market movements. CDT has a correlation of 0.05 to the broad based SPY ETF.
CDT has a market cap of $53,951.00. This is considered a Sub-Micro Cap stock.
In the last 3 years, CDT traded as high as $587,249,900.00 and as low as $.05.
CDT has underperformed the market in the last year with a price return of -100.0% while the SPY ETF gained +12.5%. CDT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -99.9% and -70.2%, respectively, while the SPY returned +2.4% and -0.8%, respectively.
CDT support price is $.06 and resistance is $.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CDT shares will trade within this expected range on the day.